CLINICAL TRIALS PROFILE FOR ASCLERA
✉ Email this page to a colleague
All Clinical Trials for ASCLERA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02657252 ↗ | Polidocanol Versus Glucose Treatment of Telangiectasia Trial | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2015-01-01 | It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety. |
| NCT02657252 ↗ | Polidocanol Versus Glucose Treatment of Telangiectasia Trial | Completed | UPECLIN HC FM Botucatu Unesp | Phase 4 | 2015-01-01 | It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety. |
| NCT06120036 ↗ | Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas | Recruiting | Johns Hopkins University | Phase 1 | 2022-12-06 | This study will evaluate the tolerability and effectiveness of two treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: Kybella and Asclera injection. Each patient will have a treatment and a control site. |
| NCT06120036 ↗ | Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas | Recruiting | Massachusetts General Hospital | Phase 1 | 2022-12-06 | This study will evaluate the tolerability and effectiveness of two treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: Kybella and Asclera injection. Each patient will have a treatment and a control site. |
| NCT06132165 ↗ | Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas | Recruiting | Johns Hopkins University | Phase 1 | 2024-03-01 | This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site.. |
| NCT06132165 ↗ | Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas | Recruiting | Massachusetts General Hospital | Phase 1 | 2024-03-01 | This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site.. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ASCLERA
Condition Name
Clinical Trial Locations for ASCLERA
Trials by Country
Clinical Trial Progress for ASCLERA
Clinical Trial Phase
Clinical Trial Sponsors for ASCLERA
Sponsor Name
